Latest Strategic Development News

Nyrada has secured AU$12.0 million from institutional and sophisticated investors, with a further AU$2.0 million shareholder purchase plan planned, giving the biotech funding to advance its Xolatryp clinical programs. The raise also carries substantial dilution and an unusually large proposed director subscription worth AU$5.125 million, subject to shareholder approval.

Carnaby Resources has made significant strides at its Greater Duchess Copper Gold Project, delivering a robust Pre-Feasibility Study and consolidating ownership, before agreeing to a $213 million acquisition by Evolution Mining offering shareholders a 60% premium.

Kingfisher Mining’s first drilling at Stephens Trig since 2017 confirms significant high-grade silver, lead, and zinc mineralisation, reinforcing its Broken Hill portfolio and strategic development options.

West Cobar Metals is broadening its scandium exploration at Salazar by adding the Benriach Prospect to its Q4 2026 air-core drilling program, aiming to tap near-surface scandium enrichment and higher-grade zones within its existing resource.

NTAW Holdings reported a 15.7% revenue drop to $445.3 million in FY2026 but improved net losses and operating EBITDA amid a strategic reset. The company divested its South African stake and plans asset sales as it targets modest growth in FY2027.

Steadfast Group delivered double-digit underlying EBITA growth in FY26 alongside a recommended $6 per share acquisition offer, reflecting a premium of nearly 52%. The insurer broker network continues to expand, supported by technology upgrades and international acquisitions.

Atomic Eagle has re-established a 60% interest in Niger’s Madaouela Uranium Project, adding 116.5 million pounds of uranium resource to its portfolio alongside its flagship Muntanga asset in Zambia, creating a substantial dual-asset platform.

Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.

Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.

Carnaby Resources has released final drill results from the Greater Duchess Project, confirming two key discoveries with significant copper-gold mineralisation. The company is advancing development plans ahead of a proposed Evolution Mining acquisition.

Far East Gold Ltd (ASX: FEG) has explained the delayed filing of a director’s interest change notice, attributing the lag to the off-market takeover bid process by Xingye Gold. The company is reinforcing its disclosure policies to prevent future delays.

PTR Minerals has bolstered its leadership team by appointing mineral sands veteran Colin Bwye as Non-executive Director and elevating Rob Sennitt to Managing Director, aligning with its push to develop the high-grade Rosewood Titanium Project in South Australia.